What Is KPV?
KPV peptide is one of the more intriguing compounds currently being explored across anti-inflammatory tripeptide and intestinal research circles. Composed of just three amino acids — lysine, proline, and valine — it is a C-terminal fragment of alpha-melanocyte-stimulating hormone (α-MSH), a 13 amino acid endogenous peptide hormone considered to play a role in metabolic functions and other biological processes. Researchers identified KPV as the primary amino acid sequence responsible for α-MSH’s biological activity, making it a focused research tool for studying the anti-inflammatory properties of this hormone class in laboratory models.
A foundational 1989 study explored the isolation and biological potential of the KPV tripeptide, with researchers conducting preliminary laboratory work to assess its potential to moderate excessive vasopermeability and blood vessel swelling in experimental models. The study concluded that the isolated fragment appeared to inhibit swelling in these models, establishing the anti-inflammatory basis for KPV’s subsequent research profile. Researchers proposed that KPV’s anti-inflammatory potential may involve inactivating inflammatory pathways and possibly inhibiting the synthesis and release of pro-inflammatory cytokines in intestinal and immune cells in laboratory settings.
KPV Peptide and Intestinal Research
At the core of KPV’s research profile is its proposed anti-inflammatory potential in intestinal cell laboratory models, where it has been studied across multiple experimental frameworks.
Research by Dalmasso et al. explored KPV’s potential in inflamed intestinal cell cultures, with findings suggesting that even nanomolar concentrations of the peptide appeared to produce anti-inflammatory effects in laboratory settings. Researchers proposed that the peptide’s action might be mediated through PepT1 expression in these intestinal cells, suggesting PepT1 may play a role in transporting this alpha-MSH peptide fragment to inflammation sites in laboratory models.
Research by Xiao et al. investigated KPV’s potential in addressing ulcerative inflammation of colonic mucosa cells in laboratory settings, with researchers proposing that KPV might moderate inflammatory responses within colonic cells by promoting mucosal healing and reducing inflammation. The findings suggested that KPV may protect mucosal surfaces and downregulate TNF-α, a key inflammatory marker, in these laboratory models.
Further research by Kannengiesser et al. using two murine models of intestinal inflammation reported significant improvements following KPV exposure, including earlier recovery, weight regain, and reduced inflammatory infiltrates in colonic tissue in laboratory settings. A notable decrease in myeloperoxidase activity was also observed, indicating reduced neutrophil accumulation and inflammation in these models. Researchers further suggested that KPV’s anti-inflammatory interactions may be at least partially independent of MC1R signaling in these laboratory settings.
A 1984 study further explored KPV’s potential antipyretic interactions in rabbit laboratory models, with results suggesting that KPV exhibited antipyretic potential, reducing body temperature toward optimal levels in these experimental conditions.
KPV Peptide and Intestinal Protection Research
Building on its intestinal inflammation research profile, KPV has also been studied for its potential protective interactions with intestinal tissue in laboratory models. Research in murine models of induced bowel dysfunction found that models exposed to the peptide exhibited a reduction in inflammatory cells and anti-enzymatic symptoms in laboratory settings.
Additional research using a murine model of intestinal inflammation involved exposure to a compound of KPV and hyaluronic acid, designed to facilitate targeted delivery of KPV to specific intestinal locations in laboratory models. Findings indicated a reduction in intestinal swelling, suggesting the peptide’s potential influence in reducing inflammation when delivered in combination with hyaluronic acid in these experimental settings.
KPV Peptide and Anti-Inflammatory Research Comparisons
A comparative laboratory study evaluated the interactions of α-MSH and KPV on organ inflammation in murine models with induced ear swelling. Both groups showed similar improvement in reducing ear swelling after 24 hours in laboratory settings. Researchers noted that most of the anti-inflammatory activities of α-MSH can be attributed to its C-terminal tripeptide KPV, directly establishing this anti-inflammatory tripeptide as the primary active fragment of the larger hormone in these experimental models.
KPV Peptide and Wound Healing Research
Beyond its intestinal and anti-inflammatory research profile, KPV has also been studied for its potential interactions with wound healing processes in laboratory models. Researchers noted that most cells involved in wound healing express the melanocortin 1 receptor, where α-MSH binds, and proposed that analogs such as KPV may also interact with these receptors in laboratory settings.
Research by Bonfiglio et al. investigated KPV’s potential in corneal epithelial wound healing laboratory models, applying varying concentrations of the peptide to mechanically damaged corneal tissue. Within 60 hours, all corneas exposed to KPV appeared to exhibit complete re-epithelialization in these laboratory models, contrasting with the control group where none achieved full healing within the same timeframe. Experiments using a nitric oxide inhibitor appeared to impede the accelerated healing effect of KPV in these laboratory models, suggesting that KPV’s positive interactions with corneal epithelial wound healing may be linked to nitric oxide dynamics in tissue. In vitro experiments with corneal epithelial cells also indicated increased cell viability at concentrations of 1 and 10 μM in laboratory settings.
Research by de Souza et al. further explored KPV’s potential in scar recovery using murine models. Observations on days 3 and 7 post-incision indicated improved skin healing in peptide-exposed models, potentially attributed to reduced levels of inflammatory cells including leukocytes and mast cells. By days 40 and 60, peptide-exposed models exhibited smaller scar areas compared to control groups in these laboratory settings.
KPV Peptide and Tumor Cell Research
Research by Viennois et al. explored KPV’s potential interactions with tumor cell development in laboratory models of colitis-related carcinogenesis. In AOM/DSS-induced murine models of colon cancer, KPV appeared to significantly reduce tumor incidence and proliferation of malignant colonic epithelial cells in a PepT1-dependent manner in these laboratory settings, suggesting a possible interaction between this alpha-MSH peptide fragment’s anti-inflammatory properties and tumor cell biology in these experimental models.
In a separate laboratory investigation using APCMin/+ mice, a genetic model prone to intestinal adenocarcinoma, KPV did not alter the incidence of tumors in either the small intestine or the colon. However, the data suggested anti-inflammatory interactions as indicated by reductions in intestinal inflammation markers such as lipocalin-2 in these models. Researchers concluded that despite modest interactions with tumorigenesis in this rigorous model, KPV effectively moderated inflammation in this model of inflammation-induced carcinogenesis in laboratory settings. These findings underscore the context-dependent nature of KPV’s interactions across different laboratory tumor models and highlight the importance of careful, controlled experimental design in this area of anti-inflammatory tripeptide research.
References
- National Center for Biotechnology Information. PubChem Compound Summary for CID 125672, L-Valine, N-(1-L-lysyl-L-prolyl). 2024.
- Hiltz ME, Lipton JM. Antiinflammatory activity of a COOH-terminal fragment of the neuropeptide alpha-MSH. FASEB J. 1989;3(11):2282–4.
- Dalmasso G, et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166–78.
- Xiao B, et al. Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis. Mol Ther. 2017;25(7):1628–1640.
- Kannengiesser K, et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis. 2008;14(3):324–31.
- Richards B, Lipton JM. Effect of α-MSH 11-13 on fever in the rabbit. Peptides. 1984;5(4):815–817.
- Kannengiesser K, et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models. Inflamm Bowel Dis. 2008;14(3):324–331.
- Brzoska T, et al. Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo. Endocr Rev. 2008;29(5):581–602.
- Bonfiglio V, et al. Effects of the COOH-terminal tripeptide alpha-MSH(11-13) on corneal epithelial wound healing. Exp Eye Res. 2006;83(6):1366–72.
- de Souza KS, et al. Improved cutaneous wound healing after intraperitoneal injection of alpha-melanocyte-stimulating hormone. Exp Dermatol. 2015;24(3):198–203.
- Viennois E, et al. Critical role of PepT1 in promoting colitis-associated cancer and therapeutic benefits of the anti-inflammatory PepT1-mediated tripeptide KPV. Cell Mol Gastroenterol Hepatol. 2016;2(3):340–357.
Disclaimer: The information provided is intended solely for educational and scientific discussion. The compounds described are strictly intended for laboratory research and in-vitro studies only. They are not approved for human or animal consumption, medical use, or diagnostic purposes. Handling is prohibited unless performed by licensed researchers and qualified professionals in controlled laboratory environments.
